BioCryst Pharma (BCRX) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioCryst Reports Fourth Quarter & Full Year 2015 Financial Results
February 23, 2016 6:50 AM ESTRESEARCH TRIANGLE PARK, N.C., Feb. 23, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2015.Â
In 2015, we gained clarity on both of our HAE drug candidates and brought in additional capital by out-licensing... More
